Metformin treatment does not inhibit growth of pancreatic cancer patient-derived xenografts

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Lipner, Matthew B ^a,b   Marayati, Raoud ^b   Deng, Yangmei ^b   Wang, Xianxi ^b   Raftery, Laura ^c   O'Neil, Bert H ^d   Yeh, Jen Jen ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c ProHealth Care Regional Cancer Center   (United States)

^d INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; DACTOLISIB; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; RAPAMYCIN; ANTIDIABETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PROTEIN KINASE INHIBITOR; S6 KINASE; TARGET OF RAPAMYCIN KINASE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE MARKER; DRUG MEGADOSE; ELECTROPHORESIS; ENZYME ACTIVATION; EXPRESSION VECTOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; GENE EXPRESSION; GENETICS; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; TUMOR VOLUME;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; GENE EXPRESSION; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MICE; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84955289535     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0147113     Document Type: Article

References (45)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA: a cancer journal for clinicians 60: 277-300.
2. Chaulagain CP, Ng J, Wazer D, SaifMW(2012) Adjuvant therapy of pancreatic cancer. JOP: Journal of the pancreas 13: 349-353. doi: 10.6092/1590-8577/935 PMID: 22797387
3. Vakana E, Altman JK, Platanias LC (2012) Targeting AMPK in the treatment of malignancies. Journal of cellular biochemistry 113: 404-409. doi: 10.1002/jcb.23369 PMID: 21928327
4. Inoki K, Kim J, Guan KL (2012) AMPK and mTOR in cellular energy homeostasis and drug targets. Annual review of pharmacology and toxicology 52: 381-400. doi: 10.1146/annurev-pharmtox-010611- 134537 PMID: 22017684
5. Carling D, Mayer FV, Sanders MJ, Gamblin SJ (2011) AMP-activated protein kinase: nature's energy sensor. Nature chemical biology 7: 512-518. doi: 10.1038/nchembio.610 PMID: 21769098
6. Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nature reviews Cancer 4: 335-348. PMID: 15122205
7. Sabatini DM (2006) mTOR and cancer: insights into a complex relationship. Nature reviews Cancer 6: 729-734. PMID: 16915295
8. Hardie DG, Ross FA, Hawley SA (2012) AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nature reviews Molecular cell biology 13: 251-262. doi: 10.1038/nrm3311 PMID: 22436748
9. Pollak MN (2012) Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer discovery 2: 778-790. doi: 10.1158/2159-8290.CD-12-0263 PMID: 22926251
10. Bolster DR, Crozier SJ, Kimball SR, Jefferson LS (2002) AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. The Journal of biological chemistry 277: 23977-23980. PMID: 11997383
11. Hardie DG (2008) AMPK and Raptor: matching cell growth to energy supply. Mol Cell 30:263-265. doi: 10.1016/j.molcel.2008.04.012 PMID: 18471972
12. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, et al. (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30:214-226. doi: 10.1016/j.molcel. 2008.03.003 PMID: 18439900
13. Shaw RJ (2009) LKB1 and AMP-activated protein kinase control of mTOR signaling and growth. Acta Physiol (Oxf) 196:65-80
14. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D (2012) Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 18: 2905-2912.
15. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. The BMJ 330: 1304-1305. PMID: 15849206
16. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, and Evans JM (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes care 32: 1620-1625. doi: 10.2337/dc08-2175 PMID: 19564453
17. Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, Catapano A, et al. (2012) Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. The oncologist 17: 813-822. doi: 10.1634/theoncologist.2011-0462 PMID: 22643536
18. Bao B, Wang Z, Ali S, Ahmad A, Azmi AS, Sarkar SH, et al. (2012) Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer prevention research 5: 355-364. doi: 10.1158/1940-6207.CAPR-11-0299 PMID: 22086681
19. Kim YD, Park KG, Lee YS, Park YY, Kim DK, Nedumaran B, et al. (2008) Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 57: 306-314. PMID: 17909097
20. Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E (2009) Metformin disrupts crosstalk between G proteincoupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer research 69: 6539-6545. doi: 10.1158/0008-5472.CAN-09-0418 PMID: 19679549
21. Lonardo E, Cioffi M, Sancho P, Sanchez-Ripoll Y, Trabulo SM, Dorado J, et al. (2013) Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. PLoS One 8: e76518. doi: 10.1371/journal.pone.0076518 PMID: 24204632
22. Wang LW, Li ZS, Zou DW, Jin ZD, Gao J, Xu GM (2008) Metformin induces apoptosis of pancreatic cancer cells. World journal of gastroenterology: WJG 14: 7192-7198. PMID: 19084933
23. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, et al. (2006) An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 12: 4652-4661. PMID: 16899615
24. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. (2012) Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 9: 338-350. doi: 10.1038/nrclinonc.2012.61 PMID: 22508028
25. Rubio-Viqueira B, Hidalgo M (2009) Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Ther 85: 217-221. doi: 10.1038/clpt.2008.200 PMID: 19005462
26. Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, et al. (2014) Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 4: 998-1013. doi: 10.1158/2159-8290.CD-14-0001 PMID: 25185190
27. Gao H, Korn JM, Ferretti S, Monahan JE, Wang Y, Signh M, et al. (2015) High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nature medicine 21: 1318-1325. doi: 10.1038/nm.3954 PMID: 26479923
28. Neel NF, Stratford JK, Shinde V, Ecsedy JA, Martin TD, Der CJ, Yeh JJ (2013) Response to MLN8237 in Pancreatic Cancer Is Not Dependent on RalA Phosphorylation. Molecular cancer therapeutics 13: 122-33. doi: 10.1158/1535-7163.MCT-12-1232 PMID: 24222664
29. Torphy RJ, Tignanelli CF, Kamande JW, Moffitt RA, Herrera Loeza SG, Soper SA, Yeh JJ (2014) Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma. PLoS One 9: e89474. doi: 10.1371/journal.pone.0089474 PMID: 24586805
30. Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, et al. (2010) Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. The Journal of clinical investigation 120: 2355-2369. doi: 10.1172/JCI40671 PMID: 20577053
31. Wilcock C, Bailey CJ (1990) Sites of metformin-stimulated glucose metabolism. Biochemical pharmacology 39: 1831-1834. PMID: 2111705
32. Martin-Montalvo A, Mercken EM, Mitchell SJ, Palacios HH, Mote PL, Scheibye-Knudsen M, et al. (2013) Metformin improves healthspan and lifespan in mice. Nature communications 4: 2192. doi: 10. 1038/ncomms3192 PMID: 23900241
33. Kawanami T, Takiguchi S, Ikeda N, Funakoshi A (2012) A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells. Oncology reports 27: 867-872. doi: 10.3892/or.2011.1597 PMID: 22200743
34. Feng YH, Velazquez-Torres G, Gully C, Chen J, Lee MH, Yeung SC (2011) The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. Journal of cellular and molecular medicine 15: 825-836. doi: 10.1111/j.1582-4934.2010.01083.x PMID: 20455996
35. Kordes S, Pollak MN, Zwinderman AH, Mathot RA, Weterman MJ, Beeker A, et al. (2015) Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncology 16: 839-847. doi: 10.1016/S1470-2045(15)00027-3 PMID: 26067687
36. Braghiroli MI, de Celis Ferrari AC, Pfiffer TE, Alex AK, Nebuloni D, Carneiro AS, et al. (2015) Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas. Ecancermedicalscience 11: 563.
37. Pollak M (2012) Metformin and pancreatic cancer: a clue requiring investigation. Clinical cancer research: an official journal of the American Association for Cancer Research 18: 2723-2725.
38. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N (2007) Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer research 67: 10804-10812. PMID: 18006825
39. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer research 66: 10269-10273. PMID: 17062558
40. Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN, Bruchim I (2008) In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecologic oncology 110: 246-250. doi: 10.1016/j.ygyno.2008.04.008 PMID: 18495226
41. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, et al. (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27: 3576-3586. doi: 10.1038/sj.onc.1211024 PMID: 18212742
42. Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P, et al. (2011) Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer research 71: 4366-4372. doi: 10.1158/0008-5472.CAN-10-1769 PMID: 21540236
43. Rattan R, Giri S, Hartmann LC, Shridhar V (2011) Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. Journal of cellular and molecular medicine 15: 166-178. doi: 10. 1111/j.1582-4934.2009.00954.x PMID: 19874425
44. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA (2009) The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell cycle 8: 88-96. PMID: 19106626
45. Li W, Yuan Y, Huang L, Qiao M, Zhang Y (2012) Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells. Diabetes research and clinical practice 96: 187-195. doi: 10.1016/j. diabres.2011.12.028 PMID: 22245693